Baidu
map

Clinica Chimica Acta:首次急性心肌梗死中脂蛋白(a)与低密度脂蛋白胆固醇的相互作用如何?

2020-02-06 Gladiator MedSci原创

本研究在中国汉族人群探讨脂蛋白(a)与低密度脂蛋白胆固醇(LDL-C)于首次急性心肌梗死(AMI)发病中的相互作用。研究人员对1522例和1691例对照组进行回顾性分析,并所有受试者按Lp(a)或LDL-C水平分组。

本研究在中国汉族人群探讨脂蛋白(a)与低密度脂蛋白胆固醇(LDL-C)于首次急性心肌梗死(AMI)发病中的相互作用。研究人员对1522例和1691例对照组进行回顾性分析,并所有受试者按Lp(a)LDL-C水平分组。

研究结果显示,与对照组(LDL-C < 2.6 mmol/L,且在Lp(a)的前1 / 5)相比,多变量校正分析显示,仅针对较高LDL-C的首次入射AMIOR95CI)为2.66 1.78–3.98); Lpa)的五分位数中单独较高Lpa)的ORs95CI)为1.511.07-2.15),1.841.28-2.64),1.861.30-2.67)和2.661.88-3.76); 较高的LDL-C和较高的Lpa)的ORs95CI)分别为3.952.64-5.92),3.202.21-4.64),5.643.80-8.36)和7.484.90-11.44 大于Lpa)五分位数中两个人的风险之和。在Lpa)的第4和第5五分位数,由于相互作用引起的相对过量风险分别为1.7895CI0.12–3.44P = 0.036)和3.010.58–5.44P = 0.015),证实存在加性相互作用 在初始AMILpa)和LDL-C之间,进一步表明了在初始AMILp(a)LDL-C之间存在附加相互作用。

研究结果表明,在中国汉族人群中,首次发生的AMI Lpa)与LDL-C存在相互作用。同时暴露于升高的Lpa)与升高的LDL-C引起的初始AMI的风险要远大于两者单独暴露的总和。

原始出处:

YongHuJian-Ying TaoInteraction of lipoprotein(a) with low-density lipoprotein cholesterol on first incident acute myocardial infarction

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849835, encodeId=37891849835c3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun May 24 11:17:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909294, encodeId=6e631909294e5, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 22 05:17:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424767, encodeId=32a51424e6716, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471652, encodeId=79a814e165278, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=)]
    2020-05-24 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849835, encodeId=37891849835c3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun May 24 11:17:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909294, encodeId=6e631909294e5, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 22 05:17:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424767, encodeId=32a51424e6716, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471652, encodeId=79a814e165278, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849835, encodeId=37891849835c3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun May 24 11:17:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909294, encodeId=6e631909294e5, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 22 05:17:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424767, encodeId=32a51424e6716, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471652, encodeId=79a814e165278, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849835, encodeId=37891849835c3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun May 24 11:17:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909294, encodeId=6e631909294e5, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 22 05:17:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424767, encodeId=32a51424e6716, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471652, encodeId=79a814e165278, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Feb 08 14:17:00 CST 2020, time=2020-02-08, status=1, ipAttribution=)]
    2020-02-08 ylz8405
Baidu
map
Baidu
map
Baidu
map